Generic Name and Formulations:
Ranibizumab 6mg/mL (0.3mg), 10mg/mL (0.5mg); soln for oph intravitreal inj; preservative-free.
Indications for LUCENTIS:
Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Diabetic macular edema (DME). Diabetic retinopathy (DR). Myopic choroidal neovascularization (mCNV).
Give by intravitreal inj. AMD: 0.5mg once a month (approx. 28 days); or 3 monthly doses followed by less frequent dosing (less effective); or 0.5mg every 3 months after 4 monthly doses (less effective). Monitor regularly. RVO: 0.5mg once a month (approx. 28 days). DME, DR: 0.3mg once a month (approx. 28 days). mCNV: 0.5mg once a month (approx. 28 days) for up to 3 months; may retreat if needed.
Ocular or periocular infections.
Monitor intraocular pressure prior to and 30 mins after inj. Monitor for perfusion of optic nerve and for infection following the inj (endophthalmitis and retinal detachments possible). Pregnancy; may cause embryo-fetal toxicity. Nursing mothers.
Vascular endothelial growth factor (VEGF) inhibitor.
Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, intraocular inflammation; rare: arterial thromboembolic events, fatal events.
Single-use prefilled syringe, single-use vial (6mg/mL, 10mg/mL)—1